Sent this to the Barron's writer who did the NVAX
Post# of 36568
(Total Views: 471)
Posted On: 06/04/2021 6:45:22 AM
Sent this to the Barron's writer who did the NVAX piece on 6/2:
Josh,
Thanks for the update on Novavax's progress. I am looking forward to seeing the results of the trial. We need as many options as we can get.
I thought you might be interested in learning about another companies vaccine research progress. Generex Biotechnology, formerly a NAZ traded company, has a subsidiary NuGenerex Immuno-oncology about to file for an IND application for their Covid vaccine trial. I realize it sounds early in the process but based on GNBT/NGIO long history and previous studies with past coronavirus's, the vaccine studies will be fairly quick, possibly concluding around the first of the year. Safety isn't in question and the main advantage is expected to be long term immunity vs vaccines currently available. The other interesting part of this story would be the financial side as Generex has spun off NGIO into a public company and is preparing an IPO and trading on the NAZ for NuGenerex Immuno-oncology. It is a pretty cool story full of twists and turns you might be interested in for your readers at Barron's. Generex itself was back in the day one of the most actively traded NAZ stocks.
I included Generex's CEO Joeseph Moscato on this note and would be interested for you gentleman to talk. Great story to be told regarding what Generex has accomplished in a very challenging environment.
Warm regards,
xxxxxxxxxxxxxxxxxxxxx
https://generex.com/
https://nugenerexio.com/
Josh,
Thanks for the update on Novavax's progress. I am looking forward to seeing the results of the trial. We need as many options as we can get.
I thought you might be interested in learning about another companies vaccine research progress. Generex Biotechnology, formerly a NAZ traded company, has a subsidiary NuGenerex Immuno-oncology about to file for an IND application for their Covid vaccine trial. I realize it sounds early in the process but based on GNBT/NGIO long history and previous studies with past coronavirus's, the vaccine studies will be fairly quick, possibly concluding around the first of the year. Safety isn't in question and the main advantage is expected to be long term immunity vs vaccines currently available. The other interesting part of this story would be the financial side as Generex has spun off NGIO into a public company and is preparing an IPO and trading on the NAZ for NuGenerex Immuno-oncology. It is a pretty cool story full of twists and turns you might be interested in for your readers at Barron's. Generex itself was back in the day one of the most actively traded NAZ stocks.
I included Generex's CEO Joeseph Moscato on this note and would be interested for you gentleman to talk. Great story to be told regarding what Generex has accomplished in a very challenging environment.
Warm regards,
xxxxxxxxxxxxxxxxxxxxx
https://generex.com/
https://nugenerexio.com/
(10)
(0)